Gaining Notoriety, SORL1 Claims Spot Among Top Alzheimer’s Genes
Recent studies have identified rare loss-of-function variants that cause Alzheimer’s with nearly 100 percent penetrance. Now there are 17 more.
ALL NEWS
6566 RESULTS
Sort By:
- Most Recent
- Most Commented
Hanging in There: Another BACE Inhibitor Still Safe in Phase 2
In 18-month data from a small trial, elenbecestat appeared well-tolerated, with no signs of liver toxicity. PET imaging indicated a drop in brain amyloid, while clinical endpoints trended toward a slowing of cognitive decline.
NIH Summit Wraps Up with Recommendations for Research
Outcomes emphasize big data, new technology, environmental and genetic risk in hopes of enabling precision medicine.
2018 Alzheimer’s Disease Research Summit
Big Data Was the Big Theme at Shortened NIH Summit NIH Summit Wraps Up with Recommendations for Research 2018 Alzheimer’s Disease Research Summit
Culling Connection From Chaos, Alzheimer’s Genetic Network Study Pins PLXNB1 and INPPL1
Making deeper inroads into Alzheimer’s systems biology, groups of genes co-expressed in the cortex associated with clinical and pathological traits of the disease, notably the slope of cognitive decline.
ZFAND1 Triggers Proteasomal Clearance of Stress Granules
New data suggest that the proteasome takes the first stab at dissolving these protein conglomerates, with autophagy coming in later to mop up.
Exercise Program Fails to Ease Dementia
Contradicting current opinion, a randomized trial made people stronger but, if anything, left their mental function weaker. What gives?
At AAN, Sights Set on Antisense Therapies for Diseases of the Brain
Antisense oligonucleotides are raising hopes for tackling a wide range of brain disorders—is the enthusiasm warranted?
American Academy of Neurology 2018 Annual Meeting
As RNA Therapies Come of Age, Efficacy Remains Weak At AAN, Sights Set on Antisense Therapies for Diseases of the Brain New Alzheimer’s and Parkinson’s Immunotherapy Data at AAN Will RNA molecules that bump up or tamp down gene expression live up to their
As RNA Therapies Come of Age, Efficacy Remains Weak
At AAN, the latest data from Phase 3 trials and open-label extensions of RNA-targeting therapies reveal a bit of benefit, but no cure.
No REST for the Brainy: Human Evolution Linked to Diseases of Aging
Genetic adaptations that gave humans their smarts may promote diseases of aging, including cancer, Alzheimer’s, and Parkinson’s. One adaptation counteracted REST, a proposed protector against AD.
Bad Synergy—Together, Vascular Problems and Aβ Hasten Memory Slippage
High vascular risk scores and Aβ burden independently associate with cognitive decline, but combined, they speed things up.
U.S. Study Says Lithium in Tap Water Does Not Fend Off Dementia
Prior evidence for protective effect evaporates after adjustment for demographic differences in high- and low-lithium communities.
Cerebrovascular Disease: Does Tau Mediate Cognitive Decline?
PET study finds tau signal associated with markers of cerebrovascular disease and cognitive issues.
To Deliver Itself From Cell to Cell, Phospho-Tau Uses UPS
Not the brown trucks with the friendly delivery guys: UPS as in unconventional protein secretion pathway. Tau rides it to slink out of one cell, and, grabbing onto heparin sulfate proteoglycans, enter another.
Current Filters
No filters selected